Ratings Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.9 ^USD	+2.63%		+8.33%	-32.29%

May. 13	Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024
May. 13	Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOURNEY MEDICAL CORPORATION	-32.29%	78.05M	-
ELI LILLY AND COMPANY	+40.73%	739B	C+
NOVO NORDISK A/S	+32.83%	598B	B
JOHNSON & JOHNSON	-6.30%	353B	C+
MERCK & CO., INC.	+15.15%	318B	B-
ABBVIE INC.	+4.05%	285B	C+
ASTRAZENECA PLC	+15.00%	240B	B+
ROCHE HOLDING AG	-5.52%	206B	A+
AMGEN INC.	+6.17%	164B	C+
PFIZER, INC.	-0.45%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes